Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Rishi Wadhera

General Cardiology · BIDMC

View

Dr. Robert Harrington

General Cardiology · WCM

View

Dr. Mike Gaziano

General Cardiology · BWH

View

Dr. Tyler Gluckman

General Cardiology · Providence

View

Dr. Cayla Pichan

General Cardiology · UT Southwestern

View

Dr. Sanjiv Kaul

General Cardiology · OHSU

View

Dr. Emily Lau

General Cardiology · MGH

View

Dr. Sarah Ashley

General Cardiology · Emory University Hospital

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.

    Aug 8, 2024DOI: 10.1161/hcq.0000000000000132Journal ArticleAHA

    Written by: Michelle M KittlesonKhadijah BreathettBoback ZiaeianDavid AguilarVanessa BlumerBiykem BozkurtRebecca L DiekemperMichael P DorschPaul A HeidenreichCorrine Y JurgensPrateeti KhazanieGeorge Augustine KoromiaHarriette G C Van Spall

    Find these authors on Roon

    MK

    Dr. Michelle Kittleson

    Advanced Heart Failure · Cedars-Sinai

    BZ

    Dr. Boback Ziaeian

    General Cardiology · UCLA

    Summary

    This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs and is meant to serve as a focused update of the "2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures." The new performance measures are taken from the "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines" and are selected from the strongest recommendations (Class 1 or Class 3). In contrast, quality measures may not have as much evidence base and generally comprise metrics that might be useful for clinicians and health care organizations for quality improvement but are not yet appropriate for public reporting or pay-for-performance programs. New performance measures include optimal blood pressure control in patients with heart failure with preserved ejection fraction, the use of sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction, and the use of guideline-directed medical therapy in hospitalized patients. New quality measures include the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with mildly reduced and preserved ejection fraction, the optimization of guideline-directed medical therapy prior to intervention for chronic secondary severe mitral regurgitation, continuation of guideline-directed medical therapy for patients with heart failure with improved ejection fraction, identifying both known risks for cardiovascular disease and social determinants of health, patient-centered counseling regarding contraception and pregnancy risks for individuals with cardiomyopathy, and the need for a monoclonal protein screen to exclude light chain amyloidosis when interpreting a bone scintigraphy scan assessing for transthyretin cardiac amyloidosis.
    BZDr. Boback Ziaeian

    Dr. Boback Ziaeian

    Cardiology · General Non-Invasive Cardiology
    University of California, Los Angeles
    boback